Soros Fund Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Soros Fund Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-137,000	Closed	-$10M	–	270
2023 Q3	$10M	Buy	+137,000	New	+$10.9M	0.14%	126

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

CHP

Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Soros Fund Management's XBI Position: Q4 2023 in Review

Soros Fund Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 137,000 shares — an estimated $10M sold.

Soros Fund Management first reported a position in XBI in Q3 2023 and held it in 1 quarter. The position peaked at $10M in Q3 2023. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

Soros Fund Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
Soros Fund Management sold 137,000 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $10M.
Soros Fund Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2023 and held it in 1 quarter.
Soros Fund Management's State Street SPDR S&P Biotech ETF position peaked at $10M in Q3 2023.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on Soros Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.